- RION has entered a collaboration with Lonza for the cGMP manufacture of its Purified Exosome Product™ (PEP™) drug substance.
- The agreement covers late-phase clinical supply and potential commercial-scale production at Lonza’s Houston facility.
RION, a commercial and clinical-stage regenerative medicine company, has signed a collaboration with Lonza, one of the world’s largest contract development and manufacturing organisations (CDMOs). The partnership will focus on cGMP manufacturing and technical support for RION’s Purified Exosome Product™ (PEP™) drug substance.
Under the agreement, Lonza will manufacture PEP™ drug substance at its Houston facility in the United States. The arrangement is designed to provide late-phase clinical supply and future commercial-scale production, supported by Lonza’s expertise in extracellular vesicles.
RION has developed a proprietary biomanufacturing platform enabling scaled production of platelet-derived exosomes. The technology underpins its pipeline of therapeutics across multiple indications, including advanced tissue regeneration, dermatology, musculoskeletal disease, pulmonary disease, cardiovascular health and women’s health.
PEP™ is formulated as a lyophilised powder with immunomodulatory, anti-inflammatory, and tissue regenerative properties. It can be administered through several routes, allowing application across a wide range of clinical areas.
“This collaboration with Lonza ensures that our proprietary exosome manufacturing platform can be scaled to meet clinical and future commercial demand,”.
Atta Behfar, Cofounder and CEO of RION
